The ‘Increasing Access to Biosimilar Act of 2023’ (HR 1352) was introduced into the US House of Representatives. The bill, if passed by Congress, would ‘require the Secretary of Health and Human Services to establish a demonstration project to increase access to biosimilar biological products under the Medicare program’. Its purpose is ‘to evaluate the benefits of providing a shared savings payment for biosimilar biological products’. The bill has been praised by the Biosimilars Forum.
Pearce IP BioBlast w/e 12 April 2024
12 APR 2024 | US | Six Regeneron Aflibercept US Patent Infringement Actions to be Centralized in West Virginia On 11 April 2024, the United States...